Biovica International AB (publ)
Research Biovica International AB (publ) (BIOVIC-B) on Bullrun: market cap SEK 106.84M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBIOVIC-B
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 106.84M
- Financial periodQ1 2026
- RevenueSEK 3.29M
- Net income-SEK 17.85M
- Free cash flow-SEK 11.56M
- Gross margin98.5%
Valuation Snapshot
latest market cap is SEK 106.84M.
About Biovica International AB (publ)
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups.
Frequently asked questions
What is Biovica International AB (publ)'s market cap?
Biovica International AB (publ)'s market capitalization is SEK 106.84M.
What does Biovica International AB (publ) do?
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer.